专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL271889B Antiproliferative compounds and methods of use thereof 未知
公开(公告)号：IL271889B
公开(公告)日：2022-11-01
申请号：IL27188920
申请日：2020-01-07
申请人： CELGENE CORP , ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ GIRONA ANTONIA , BRAY GORDON L , WONG LILLY L , CARRANCIO SORAYA , CARMICHAEL JAMES , ARTMAN GERALD D III , CATHERS BRIAN E , HAVENS COURTNEY G , KERCHER TIMOTHY S , LU XIAOLING , MAN HON WAH , NAGY MARK A , NARLA RAMA K , PICCOTTI JOSEPH R , PIERCE DANIEL W , TAVARES GRECO PAULA A , WHITEFIELD BRANDON W , ZOU NANFEI
发明人： ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ-GIRONA ANTONIA , BRAY GORDON L , WONG LILLY L , CARRANCIO SORAYA , CARMICHAEL JAMES , ARTMAN GERALD D III , CATHERS BRIAN E , HAVENS COURTNEY G , KERCHER TIMOTHY S , LU XIAOLING , MAN HON-WAH , NAGY MARK A , NARLA RAMA K , PICCOTTI JOSEPH R , PIERCE DANIEL W , TAVARES-GRECO PAULA A , WHITEFIELD BRANDON W , ZOU NANFEI
IPC分类号： A61K31/454 , A61K31/496 , A61P35/00
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

2. 发明专利

IL271889D0 Antiproliferative compounds and methods of use thereof 未知
公开(公告)号：IL271889D0
公开(公告)日：2020-02-27
申请号：IL27188920
申请日：2020-01-07
申请人： CELGENE CORP , ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ GIRONA ANTONIA , BRAY GORDON L , WONG LILLY L , CARRANCIO SORAYA , CARMICHAEL JAMES , ARTMAN GERALD D III , CATHERS BRIAN E , HAVENS COURTNEY G , KERCHER TIMOTHY S , LU XIAOLING , MAN HON WAH , NAGY MARK A , NARLA RAMA K , PICCOTTI JOSEPH R , PIERCE DANIEL W , TAVARES GRECO PAULA A , WHITEFIELD BRANDON W , ZOU NANFEI
发明人： ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ-GIRONA ANTONIA , BRAY GORDON L , WONG LILLY L , CARRANCIO SORAYA , CARMICHAEL JAMES , ARTMAN GERALD D III , CATHERS BRIAN E , HAVENS COURTNEY G , KERCHER TIMOTHY S , LU XIAOLING , MAN HON-WAH , NAGY MARK A , NARLA RAMA K , PICCOTTI JOSEPH R , PIERCE DANIEL W , TAVARES-GRECO PAULA A , WHITEFIELD BRANDON W , ZOU NANFEI
IPC分类号： A61K20060101
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

3. 发明专利

IL277435D0 Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma 未知
公开(公告)号：IL277435D0
公开(公告)日：2020-11-30
申请号：IL27743520
申请日：2020-09-17
申请人： CELGENE CORP , ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ GIRONA ANTONIA , CARRANCIO SORAYA , KERCHER TIMOTHY S , NAGY MARK A , GRANT VIRGINIA HEATHER SHARRON , HARRIS ROY L , HUANG DEHUA , PLANTEVIN KRENITSKY VERONIQUE
发明人： ALEXANDER MATTHEW D , CORREA MATTHEW D , HANSEN JOSHUA , LOPEZ-GIRONA ANTONIA , CARRANCIO SORAYA , KERCHER TIMOTHY S , NAGY MARK A , GRANT VIRGINIA HEATHER SHARRON , HARRIS ROY L , HUANG DEHUA , PLANTEVIN-KRENITSKY VERONIQUE
IPC分类号： A61P35/00
摘要： Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: Formula ( I ) wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma.

4. 发明专利

IL278854D0 Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile 未知
公开(公告)号：IL278854D0
公开(公告)日：2021-01-31
申请号：IL27885420
申请日：2020-11-20
申请人： CELGENE CORP , HANSEN JOSHUA , LOPEZ GIRONA ANTONIA , LU GANG , ANTON MARIA SORAYA CARRANCIO , HAVENS COURTNEY G , PIERCE DANIEL W , WONG LILLY L
发明人： HANSEN JOSHUA , LOPEZ-GIRONA ANTONIA , LU GANG , ANTON MARIA SORAYA CARRANCIO , HAVENS COURTNEY G , PIERCE DANIEL W , WONG LILLY L
IPC分类号： A61K31/496 , A61K45/06 , A61P35/00 , G01N33/50 , G01N33/574 , G01N33/68
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

5. 发明专利

IL262565D0 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide 未知
公开(公告)号：IL262565D0
公开(公告)日：2018-12-31
申请号：IL26256518
申请日：2018-10-24
申请人： CELGENE CORP , POURDEHNAD MICHAEL , MACBETH KYLE , LOPEZ GIRONA ANTONIA , LU GANG , CARRANCIO SORAYA , HOLLENBACH PAUL , RAPPLEY IRIT
发明人： POURDEHNAD MICHAEL , MACBETH KYLE , LOPEZ-GIRONA ANTONIA , LU GANG , CARRANCIO SORAYA , HOLLENBACH PAUL , RAPPLEY IRIT
IPC分类号： A61K20060101
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

6. 发明专利

IL262565B Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide 未知
公开(公告)号：IL262565B
公开(公告)日：2022-08-01
申请号：IL26256518
申请日：2018-10-24
申请人： CELGENE CORP , POURDEHNAD MICHAEL , MACBETH KYLE , LOPEZ GIRONA ANTONIA , LU GANG , CARRANCIO SORAYA , HOLLENBACH PAUL , RAPPLEY IRIT
发明人： POURDEHNAD MICHAEL , MACBETH KYLE , LOPEZ-GIRONA ANTONIA , LU GANG , CARRANCIO SORAYA , HOLLENBACH PAUL , RAPPLEY IRIT
IPC分类号： A61K31/454 , A61P35/02
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

7. 发明申请

WO2006113251A2 METHODS TO IDENTIFY COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE AND DIFFERENTIATIVE DISORDERS 审中-公开
标题翻译：识别化合物用于治疗增殖性和分化型疾病的方法
公开(公告)号：WO2006113251A2
公开(公告)日：2006-10-26
申请号：PCT/US2006013576
申请日：2006-04-11
申请人： UNIV NEW YORK , CELGENE CORP , PAGANO MICHELE , MERCURIO FRANK , XIE WEILIN , LOPEZ-GIRONA ANTONIA , PESCHIAROLI ANGELO
发明人： PAGANO MICHELE , MERCURIO FRANK , XIE WEILIN , LOPEZ-GIRONA ANTONIA , PESCHIAROLI ANGELO
IPC分类号： G01N33/50
CPC分类号： G01N33/5023 , A61K31/7088 , A61K38/02 , A61K38/1709 , A61K39/3955 , G01N33/573 , G01N33/574 , G01N2333/4703 , G01N2333/9015 , G01N2500/00 , G01N2500/04
摘要： The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBPl, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBPlO, FBPI l, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate- targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders.
摘要翻译：本发明涉及编码泛素连接酶的新的底物靶向亚基的核苷酸序列的发现，鉴定和表征。本发明包括编码泛素连接酶的新型底物靶向亚基的核苷酸：FBP1，FBP2，FBP3，FBP4，FBP5，FBP6，FBP7，FBP8，FBP9，FBP10，FBPI1，FBP12，FBP13，FBP14，FBP15，FBP16，FBP17，FBP18 ，FBP19，FBP20，FBP21，FBP22，FBP23，FBP24和FBP25，转基因小鼠，敲除小鼠，宿主细胞表达系统和由新型底物靶向亚基的核苷酸编码的蛋白质。本发明涉及使用泛素连接酶的新颖且已知的底物靶向亚基的筛选测定法，以鉴定潜在的治疗剂，例如调节新型和已知的泛素的活性的新型和已知的泛素连接酶的小分子，化合物或衍生物和类似物用于治疗增殖性和分化性疾病如癌症，主要机会性感染，免疫疾病，某些心血管疾病和炎症性疾病的连接酶。本发明还包括设计用于靶向泛素连接酶及其底物以治疗增殖性和分化性疾病的治疗方案和药物组合物。

8. 发明专利

IL292265D0 Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione 未知
公开(公告)号：IL292265D0
公开(公告)日：2022-06-01
申请号：IL29226522
申请日：2022-04-13
申请人： CELGENE CORP , JANARDHANAN PREETHI , KASIBHATLA SHAILAJA , LOPEZ GIRONA ANTONIA , POURDEHNAD MICHAEL
发明人： JANARDHANAN PREETHI , KASIBHATLA SHAILAJA , LOPEZ-GIRONA ANTONIA , POURDEHNAD MICHAEL
IPC分类号： A61K31/5377 , A61K39/00 , A61P35/02 , C07K16/28
摘要： Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.

9. 发明专利

IL260400B Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies 未知
公开(公告)号：IL260400B
公开(公告)日：2022-10-01
申请号：IL26040018
申请日：2018-07-03
申请人： CELGENE CORP , FILVAROFF ELLEN , LOPEZ GIRONA ANTONIA , LU GANG
发明人： FILVAROFF ELLEN , LOPEZ-GIRONA ANTONIA , LU GANG
IPC分类号： A61K31/454 , A61K45/06 , A61P35/00 , A61P35/02 , A61P43/00 , G01N33/574
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:

10. 发明专利

IL292305D0 Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione 未知
公开(公告)号：IL292305D0
公开(公告)日：2022-06-01
申请号：IL29230522
申请日：2022-04-15
申请人： CELGENE CORP , ANTON MARIA SORAYA CARRANCIO , FONTANILLO CELIA FONTANILLO , KASIBHATLA SHAILAJA , LOPEZ GIRONA ANTONIA , LU GANG , WANG KAI
发明人： ANTON MARIA SORAYA CARRANCIO , FONTANILLO CELIA FONTANILLO , KASIBHATLA SHAILAJA , LOPEZ-GIRONA ANTONIA , LU GANG , WANG KAI
IPC分类号： A61K31/5377 , A61K45/06 , A61P35/00 , G01N33/574
摘要： A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式